# Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

> **NCT06364956** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 36 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Tislelizumab combined with two predefined dose groups of palbociclib
- **DRUG:** RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.

## Key facts

- **NCT ID:** NCT06364956
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364956, "Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06364956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*